



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/373,272	08/12/1999	SANDRA AUSTIN-PHILLIPS	09820.114	2404
7590 04/20/2004 INTELLECTUAL PROPERTY DEPARTMENT			EXAMINER	
			EPPS FORD, JANET L	
DEWITT ROSS & STEVENS SC FIRSTAR FINANCIAL CENTRE		ART UNIT	PAPER NUMBER	
8000 EXCELSIOR DRIVE SUITE 401 MADISON, WI 537171914			1635 DATE MAILED: 04/20/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/373,272	AUSTIN-PHILLIPS ET AL.			
		Examiner	Art Unit			
		Janet L. Epps-Ford, Ph.D.	1635			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on 30 January 2004.					
-	This action is FINAL . 2b)⊠ This action is non-final.					
3)	- ··					
	closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11, 4	153 O.G. 213.			
Disposition of Claims						
5)□ 6)⊠	 4) Claim(s) 27,28 and 31-40 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 27-28 and 31-40 is/are rejected. 7) Claim(s) is/are objected to. 					
•	8) Claim(s) are subject to restriction and/or election requirement.					
	ion Papers					
9) The specification is objected to by the Examiner.						
10)[_]	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)[11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachmen	nt(s)					
	ce of References Cited (PTO-892)	4) Interview Summa				
3) Infor	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 er No(s)/Mail Date	Paper No(s)/Mail 5) Notice of Informal 6) Other:	Date Patent Application (PTO-152)			

DETAILED ACTION

Response to Amendment

1. The Declaration filed on 1-30-04 under 37 CFR 1.131 is sufficient to overcome the Lebel et al. reference.

Response to Arguments

2. Applicant's arguments with respect to claims 27-28 and 31-40 have been considered but are most in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 27-28 and 31-40 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. (Written Description).

The instant claims are drawn to a genetically recombinant tobacco or alfalfa plant which is stably transformed to contain and express a gene sequence which encodes *T. fusca* cellulase E2 or E3, and methods of using said recombinant plant for producing cellulose-degrading enzymes, and in methods for ensilement.

The instant disclosure provides only the nucleotide sequences of SEQ ID NO: 1 and 2, wherein said sequences encode *T. fusca* cellulase E2 and *T. fusca* cellulase E3, respectively,

Art Unit: 1635

cellulose-degrading genes. No additional nucleic acids encoding cellulose-degrading enzymes are disclosed in the specification as filed. Additionally, there is no information in the literature or in the specification as filed that would allow the skilled artisan to predict if genes within this genus are very similar or what particular structural and physical characteristics would define the claimed genus. In addition, it is not clear whether these genes will be able to produce a functional protein when expressed in a plant.

See the Guidelines for Examination of Patent Applications Under the 35 USC 112 ¶ 1, "Written Description" Requirement (Vol. 66, No. 4, pages 1099-1111). These guidelines state that: "To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. An applicant shows possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that applicant was in possession of the claimed invention."

Moreover, according to MPEP § 2163[R-1]I.A. "The claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A biomolecule sequence

Art Unit: 1635

described only by a functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence, normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence." In the instant case, Applicants have not provided sufficient structural information that would allow the skilled artisan to precisely predict the structure of the broad genus of compounds claimed by Applicants.

Therefore, with the exception of the nucleotide sequences of SEQ ID NO: 1 and 2, Applicants were not in possession of the full scope of gene sequences that encode a *T. fusca* E2 or E3 cellulase.

Art Unit: 1635

5. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Janet L. Epps-Ford, Ph.D. whose telephone number is 571-272-

0757. The examiner can normally be reached on Monday-Saturday, Flex Schedule.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, John L. LeGuyader can be reached on 571-272-0760. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit 1635

JLE